What partners and investors probe
Diligence on a biotech portfolio usually focuses on whether the claims cover the product candidate as it is actually being developed, not just the original research version. Changes during development, such as a modified sequence, a new formulation, or a different manufacturing route, can move the product outside the earliest claims. Broad claims to a class of molecules defined by what they do have become harder to sustain unless the application teaches how to make and use the full scope, and reviewers check that against the specification. Ownership is the other recurring issue, since university, hospital, and sponsor agreements often give those institutions rights in inventions made in their labs. Inventorship is checked as well, because naming the wrong scientists can cloud title, although errors can often be corrected when caught early.
Freedom to operate with platform tools
Biotech products are frequently built with tools others have patented, including expression systems, editing technologies, delivery vehicles, and cell lines. A license that covered research use may not cover commercial manufacturing or sale. U.S. law has a statutory safe harbor for activities reasonably related to developing information for FDA submissions, but the general experimental-use exception is very narrow and offers little cover for commercial research. Mapping third-party patents against the development plan early leaves time to license, design around, or challenge.
Working through the portfolio
We start with the product candidate's current form and development plan, then read the claims of each family against it. Sequence listings, deposits of biological material where needed, and the data supporting each claim are part of the review, because gaps in a filed application usually cannot be filled later. We also look at pending applications and continuations that could still be steered toward the current product. The result is a plain account of what is covered, what is exposed, and which filings or licenses should come next.
